I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation

The article highlights dividend durability in a sideways market, emphasizing AbbVie’s immunology-driven turnaround with 2026 forecasts of ~10% revenue growth and ~40% earnings growth, alongside a ~2.75% forward dividend yield and ~6% average annual dividend growth. Chevron is framed as a “Dividend King in the making,” with ~3.75% forward yield and ~6% average dividend growth, while assuming Brent >$70/bbl could support ~10% annualized earnings growth to 2030. PepsiCo is pitched as a contrarian entry at an ~4.4% forward dividend yield, trading at 18x forward earnings vs Coca-Cola’s 25x, with potential support from tariff refunds and strong international results.

Analysis

This reads more like a low-volatility factor rotation pitch than a fresh fundamental catalyst, so the edge is in relative valuation, not absolute upside. ABBV is the cleanest earnings-quality story because the market will continue paying for visible cash flow compounding if the immunology mix keeps offsetting legacy erosion; APGE is optionality, but not enough to move the near-term P&L by itself. The real question is whether the market keeps awarding ABBV a premium multiple while rates stay sticky and every other defensive healthcare name trades as a bond proxy.

CVX is a slower-burn capital-return setup: if Brent holds a floor, buybacks plus dividend growth can compound per-share value even without heroic commodity assumptions. But that works best when crude is range-bound, not surging; above that, policy and demand destruction risks rise, while below it the stock becomes just another large-cap energy yield play. The second-order winner is not necessarily CVX alone but the whole capital-disciplined integrated group versus higher-beta E&Ps that need commodity leverage to work.

PEP is the contrarian setup, but the consensus may be underestimating how long share recovery can take in U.S. snacks/beverages. If volume pressure persists, the yield becomes a cushion rather than a catalyst; if management stabilizes mix and international growth, the stock can rerate from a discount to KO on sentiment alone. Falsifier: any evidence that U.S. market share keeps bleeding into the next two quarters would make the value case a trap rather than a bargain.

Key Decisions for Investors

• Long ABBV on weakness over 3-6 months; thesis is cash-flow durability and dividend compounding, with downside if immunology growth decelerates or APGE integration distracts capital allocation.
• Pair trade: long PEP / short KO for 3-9 months if you want a relative-value staples expression; use it only if you believe PEP’s discount is overdone and the market will pay up for yield + international mix.
• Long CVX as a 6-12 month carry trade only if Brent remains above ~$70; stop out on a sustained break below that level, because the dividend-growth story loses torque quickly.
• Avoid forcing a broad defensive basket here; prefer ABBV and PEP over XLP if the goal is alpha, since the sector ETF likely dilutes the single-name valuation dislocations.